Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909110 | 0.91 | EPHX2 (0.40) | EPHX2NPY5RALDH1A1KMT2ALMNA | |
| SCHEMBL24244805 | 0.91 | EPHX2 (0.40) | EPHX2NPY5RALDH1A1KMT2ALMNA | |
| SCHEMBL19259598 | 0.86 | KMT2A (0.37) | ALDH1A1KMT2ALMNASMN1; SMN2ATM | |
| SCHEMBL24521409 | 0.86 | CPN1 (0.40) | ALDH1A1KMT2ALMNASMN1; SMN2ATM | |
| SCHEMBL21281226 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNASMN1; SMN2ATM | |
| SCHEMBL22030913 | 0.83 | CYP3A4 (0.41) | ALDH1A1KMT2ALMNASMN1; SMN2ATM | |
| SCHEMBL16509333 | 0.80 | ALDH1A1 (0.42) | EPHX2NPY5RALDH1A1 | |
| SCHEMBL12516865 | 0.79 | L3MBTL3 (0.53) | EPHX2NPY5RALDH1A1EPHX1NPC1 | |
| SCHEMBL14752986 | 0.78 | EPHX2 (0.47) | EPHX2ALDH1A1 | |
| SCHEMBL21280987 | 0.75 | KMT2A (0.41) | ALDH1A1KMT2ALMNASMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3380474-B1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | EPHX2 1119/4885NPY5R 2061/4885ALDH1A1 1102/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | EPHX2 1730/4885NPY5R 2990/4885ALDH1A1 1817/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | EPHX2 1119/4885NPY5R 2061/4885ALDH1A1 1102/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | EPHX2 1730/4885NPY5R 2990/4885ALDH1A1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.